204 related articles for article (PubMed ID: 31597436)
21. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
[TBL] [Abstract][Full Text] [Related]
22. Impact of somatic mutations on patterns of metastasis in colorectal cancer.
Lipsyc M; Yaeger R
J Gastrointest Oncol; 2015 Dec; 6(6):645-9. PubMed ID: 26697197
[TBL] [Abstract][Full Text] [Related]
23. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
[TBL] [Abstract][Full Text] [Related]
24. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
[TBL] [Abstract][Full Text] [Related]
25. Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: a nationwide cohort study.
Chen KH; Shao YY; Chen HM; Lin YL; Lin ZZ; Lai MS; Cheng AL; Yeh KH
BMC Cancer; 2016 May; 16():327. PubMed ID: 27221731
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of KRAS mutation in patients undergoing pulmonary metastasectomy for colorectal cancer: A systematic review and meta-analysis.
Huang J; Zang Q; Wen Y; Pan Z; Yao Z; Huang M; Huang J; Chen J; Wang R
Crit Rev Oncol Hematol; 2021 Apr; 160():103308. PubMed ID: 33753248
[TBL] [Abstract][Full Text] [Related]
27. Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study.
Polidoro MA; Milana F; Soldani C; Franceschini B; Anselmo A; Colombo FS; Di Tommaso L; Cimino M; Carnevale S; Lleo A; Jaillon S; Torzilli G; Donadon M
J Leukoc Biol; 2020 Aug; 108(2):715-721. PubMed ID: 32108374
[TBL] [Abstract][Full Text] [Related]
28. The current understanding on the impact of KRAS on colorectal cancer.
Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T
Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280
[TBL] [Abstract][Full Text] [Related]
29. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
[TBL] [Abstract][Full Text] [Related]
30. Mutation status and surgical selection.
Margonis GA; Kreis ME; Wolfgang CL; Weiss MJ
J Surg Oncol; 2019 Apr; 119(5):616-622. PubMed ID: 30779134
[TBL] [Abstract][Full Text] [Related]
31. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
32. The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis.
Margonis GA; Amini N; Buettner S; Kim Y; Wang J; Andreatos N; Wagner D; Sasaki K; Beer A; Kamphues C; Morioka D; Løes IM; Imai K; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Burkhart R; Endo I; Baba H; Mischinger HJ; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
Ann Surg; 2021 Jun; 273(6):1165-1172. PubMed ID: 31389831
[TBL] [Abstract][Full Text] [Related]
33. KRAS mutation status concordance between the primary tumor and the corresponding metastasis in patients with rectal cancer.
Jo P; Bernhardt M; Nietert M; König A; Azizian A; Schirmer MA; Grade M; Kitz J; Reuter-Jessen K; Ghadimi M; Ströbel P; Schildhaus HU; Gaedcke J
PLoS One; 2020; 15(10):e0239806. PubMed ID: 33002027
[TBL] [Abstract][Full Text] [Related]
34. The association of KRAS mutation with primary tumor location and survival in patients undergoing resection of colorectal cancers and synchronous liver metastases.
Allievi N; Goffredo P; Utria AF; Pisano M; Poiasina E; Lucianetti A; Zhou P; Hassan I
Chin Clin Oncol; 2019 Oct; 8(5):46. PubMed ID: 31500429
[TBL] [Abstract][Full Text] [Related]
35. Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.
Kodaz H; Erdogan B; Hacibekiroglu I; Turkmen E; Tozkir H; Albayrak D; Uzunoglu S; Cicin I
Hepatogastroenterology; 2015 Jun; 62(140):876-9. PubMed ID: 26902020
[TBL] [Abstract][Full Text] [Related]
36. Metastatic Pattern of Stage IV Colorectal Cancer with High-Frequency Microsatellite Instability as a Prognostic Factor.
Fujiyoshi K; Yamamoto G; Takenoya T; Takahashi A; Arai Y; Yamada M; Kakuta M; Yamaguchi K; Akagi Y; Nishimura Y; Sakamoto H; Akagi K
Anticancer Res; 2017 Jan; 37(1):239-247. PubMed ID: 28011498
[TBL] [Abstract][Full Text] [Related]
37. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
38. Japanese experience with hepatic resection of KRAS-mutated colorectal liver metastases.
Shindoh J
Chin Clin Oncol; 2019 Oct; 8(5):47. PubMed ID: 31500425
[TBL] [Abstract][Full Text] [Related]
39. Genetic and epigenetic alterations in primary colorectal cancers and related lymph node and liver metastases.
Miranda E; Bianchi P; Destro A; Morenghi E; Malesci A; Santoro A; Laghi L; Roncalli M
Cancer; 2013 Jan; 119(2):266-76. PubMed ID: 22786759
[TBL] [Abstract][Full Text] [Related]
40. The ALPPS Approach for Colorectal Liver Metastases: Impact of KRAS Mutation Status in Survival.
Serenari M; Alvarez FA; Ardiles V; de Santibañes M; Pekolj J; de Santibañes E
Dig Surg; 2018; 35(4):303-310. PubMed ID: 29032374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
